- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 5/08 - Tripeptides
Détention brevets de la classe C07K 5/08
Brevets de cette classe: 674
Historique des publications depuis 10 ans
|
40
|
53
|
49
|
50
|
40
|
37
|
33
|
20
|
29
|
24
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Purdue Research Foundation | 3993 |
28 |
| Bristol-myers Squibb Company | 4751 |
15 |
| ISP Investments Inc. | 440 |
15 |
| Ajinomoto Co., Inc. | 2289 |
10 |
| Hoffmann-La Roche Inc. | 3876 |
9 |
| The Regents of the University of California | 20987 |
8 |
| Onyx Therapeutics, Inc. | 65 |
8 |
| Regeneron Pharmaceuticals, Inc. | 4887 |
7 |
| Genentech, Inc. | 4161 |
6 |
| DSM IP Assets B.V. | 5405 |
6 |
| Novozymes A/S | 3408 |
6 |
| Rhythm Pharmaceuticals, Inc. | 98 |
6 |
| Boehringer Ingelheim International GmbH | 4485 |
5 |
| Agency for Science, Technology and Research | 3785 |
5 |
| InterMune, Inc. | 46 |
5 |
| Merck Sharp & Dohme LLC | 3734 |
5 |
| F. Hoffmann-La Roche AG | 7784 |
4 |
| California Institute of Technology | 4048 |
4 |
| University of Florida Research Foundation, Inc. | 4225 |
4 |
| Enanta Pharmaceuticals, Inc. | 427 |
4 |
| Autres propriétaires | 514 |